Caption Management’s Esperion Therapeutics ESPR Stock Holding History

Caption Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-119,600	Closed	-$190K	–	1182
2023 Q1	$190K	Buy	+119,600	New	+$617K	﹤0.01%	922
2022 Q3	–	Sell	-25,000	Closed	-$159K	–	1599
2022 Q2	$159K	Buy	+25,000	New	+$142K	﹤0.01%	1261
2021 Q4	–	Sell	-15,000	Closed	-$181K	–	1687
2021 Q3	$181K	Sell	15,000 -125,300	-89%	-$1.82M	﹤0.01%	1360
2021 Q2	$2.97M	Buy	140,300 +17,800	+15%	+$429K	0.04%	542
2021 Q1	$3.44M	Buy	+122,500	New	+$3.61M	0.07%	344
2020 Q4	–	Sell	-15,000	Closed	-$558K	–	1061
2020 Q3	$558K	Hold	15,000	–	–	0.01%	748
2020 Q2	$770K	Sell	15,000 -12,000	-44%	-$502K	0.03%	589
2020 Q1	$852K	Sell	27,000 -3,000	-10%	-$158K	0.05%	438
2019 Q4	$1.79M	Hold	30,000	–	–	0.06%	375
2019 Q3	$1.1M	Hold	30,000	–	–	0.06%	362
2019 Q2	$1.4M	Buy	+30,000	New	+$1.41M	0.07%	311
2019 Q1	–	Sell	-42,500	Closed	-$1.96M	–	616
2018 Q4	$1.96M	Sell	42,500 -107,500	-72%	-$5.18M	0.16%	184
2018 Q3	$6.66M	Buy	+150,000	New	+$6.89M	0.37%	74

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Caption Management's ESPR Position: Q1 2024 in Review

Caption Management sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 31,600 shares — an estimated $76.8K sold.

Caption Management first reported a position in ESPR in Q4 2018 and held it in 9 quarters. The position peaked at $1.1M in Q2 2020. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

Caption Management reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
Caption Management sold 31,600 Esperion Therapeutics shares in Q1 2024, an estimated $76.8K.
Caption Management first reported a position in Esperion Therapeutics in Q4 2018 and held it in 9 quarters.
Caption Management's Esperion Therapeutics position peaked at $1.1M in Q2 2020.
153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.